Biologics targeting T2-driven immune responses, including dupilumab (anti-IL-4Rα monoclonal antibody), represent a significant advancement in the management of asthma, especially for patients with moderate-to-severe disease where standard treatments may not provide adequate control. This evidence concerns the gene IL4R and asthma.